When it comes to small and scrappy biotechs, Batu Biologics might take the cake. Led by a 25-year-old college dropout, Batu got its start with a $100,000 infusion of cash from a crowdfunding campaign the team launched online… read the article to learn what they have accomplished since then!
Batu Biologics, a year-old startup, has filed to begin a clinical trial of its cancer vaccine, which seeks to harness the immune system to stop growth of new blood vessels that feed tumors.
San Diego-based Batu Biologics Inc., is taking a more inventive approach. Batu’s new cancer vaccine, ValloVax™, is designed to target and kill blood vessels that feed tumor growth. In doing so, Batu expects white blood cells to invade the tumor site and encourage immune-based remission.
A local biotech startup and its 22 year old CEO — with support of local industry veterans — are trying a no-strings-attached funding model to finance their research on a potential cancer vaccine.
In this video, Samuel C. Wagner, President and CEO of Batu Biologics, discusses Facciponte’s study of a TEM-1 DNA vaccination’s efficacy as a cancer therapeutic and the affect of the vaccination on healthy angiogenesis processes in the body.
Productive and beneficial relationships with cutting-edge pharmaceutical companies such as Batu Biologics help speed further development of promising new drugs to those most in need.
Her impeccable clinical trials expertise, combined with stellar interpersonal skills and keen knowledge of international markets, will serve the company well in its quest to be the first to successfully launch an anti-angiogenic lung cancer vaccine on the market.
Using a fundraising approach seldom seen in the life sciences sector, Batu Biologics, an immunotherapy company working to develop the first anti-angiogenic cancer vaccine, has successfully raised $100,000 through the Indiegogo crowdfunding platform.
The donation-based crowdfunding campaign provides non-dilutive capital to the company which accelerates our ongoing preclinical lung cancer immunological experiments needed for FDA IND submission.
Given that the majority of lung cancers are diagnosed late in progression, the majority of patients have limited treatment options, which often carry a heavy burden of toxicity.